← Leaderboards
Andrew E Aplin
Albany Medical College
$19,487,236
Attributed
$23,744,927
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,744,927 · 11
By mechanism
R01$20,230,526 · 8
P01$2,108,269 · 1
T32$1,139,306 · 1
P30$266,826 · 1
Top collaborators
- Julio A Aguirre-Ghiso5 shared
- Emad S. Alnemri5 shared
- J. Silvio Gutkind5 shared
- Bruno Calabretta3 shared
- Lucia R Languino2 shared
Others in their field
Top investigators on “Signal Transduction”
- Peter B. Gilbert · Fred Hutchinson Cancer Center$148,539,615
- David Heimbrook · Leidos Biomedical Research, Inc.$82,049,940
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$70,290,471
- Garret A Fitzgerald · University Of Pennsylvania$66,142,222
- Michael Barry Kastan · Duke University$64,512,357
- Randall J Bateman · Washington University$62,939,456
Research focus
Signal TransductionCellsMelanoma CellMelanomaMutantTumorResistanceMalignant NeoplasmsIn VivoMediatingPathway InteractionsBaseMeksGrowthInhibitor/AntagonistResponseIn VitroRegulationFutureMapk3 GeneInnovationSkin CancerTargeted TreatmentCutaneous Melanoma
Grant awards (77)
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$522,110
R01 · FY2025 · CA
Mechanisms of cell death in cutaneous melanoma$477,822
R01 · FY2025 · CA · contact PI
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$502,859
R01 · FY2024 · CA
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance$462,127
R01 · FY2024 · CA · contact PI
Mechanisms of cell death in cutaneous melanoma$453,931
R01 · FY2024 · CA · contact PI
Targeted therapies in cutaneous melanoma$351,975
R01 · FY2024 · CA · contact PI
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$525,822
R01 · FY2023 · CA
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance$472,585
R01 · FY2023 · CA · contact PI
Mechanisms of cell death in cutaneous melanoma$468,265
R01 · FY2023 · CA · contact PI
Overcoming primary and secondary resistance in wild-type BRAF melanoma$441,736
P01 · FY2023 · CA · contact PI
Targeted therapies in cutaneous melanoma$363,090
R01 · FY2023 · CA · contact PI
Training Program in Cancer Biology$142,401
T32 · FY2023 · CA
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$535,362
R01 · FY2022 · CA
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance$472,585
R01 · FY2022 · CA · contact PI
Mechanisms of cell death in cutaneous melanoma$463,189
R01 · FY2022 · CA · contact PI
Overcoming primary and secondary resistance in wild-type BRAF melanoma$368,044
P01 · FY2022 · CA · contact PI
Targeted therapies in cutaneous melanoma$363,090
R01 · FY2022 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma$363,090
R01 · FY2022 · CA · contact PI
Training Program in Cancer Biology$229,985
T32 · FY2022 · CA
Cancer Cell Biology and Signaling$50,997
P30 · FY2022 · CA · contact PI
Targeting Systems Vulnerabilities in the Gαq/GNAQ Oncogenic Signaling Circuitry: New Precision Therapies for Uveal Melanoma$565,730
R01 · FY2021 · CA
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance$478,344
R01 · FY2021 · CA · contact PI
Mechanisms of cell death in cutaneous melanoma$477,822
R01 · FY2021 · CA · contact PI
Overcoming primary and secondary resistance in wild-type BRAF melanoma$375,350
P01 · FY2021 · CA · contact PI
Targeted therapies in cutaneous melanoma$370,500
R01 · FY2021 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma$370,500
R01 · FY2021 · CA · contact PI
Training Program in Cancer Biology$247,871
T32 · FY2021 · CA
Cancer Cell Biology and Signaling$50,997
P30 · FY2021 · CA · contact PI
Overcoming primary and secondary resistance in wild-type BRAF melanoma$548,033
P01 · FY2020 · CA · contact PI
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance$497,523
R01 · FY2020 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma$370,500
R01 · FY2020 · CA · contact PI
Targeted therapies in cutaneous melanoma$370,500
R01 · FY2020 · CA · contact PI
Training Program in Cancer Biology$269,223
T32 · FY2020 · CA
Cancer Cell Biology and Signaling$50,997
P30 · FY2020 · CA · contact PI
Overcoming primary and secondary resistance in wild-type BRAF melanoma$375,106
P01 · FY2019 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma$359,385
R01 · FY2019 · CA · contact PI
Mutant BRAF-regulated transcription factors in melanoma progression$346,144
R01 · FY2019 · CA · contact PI
Training Program in Cancer Biology$249,826
T32 · FY2019 · CA
Request for Supplemental Funds aligned to CA160495$124,464
R01 · FY2019 · CA · contact PI
Cancer Cell Biology and Signaling$50,997
P30 · FY2019 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma$370,500
R01 · FY2018 · CA · contact PI
Mutant BRAF-regulated transcription factors in melanoma progression$356,850
R01 · FY2018 · CA · contact PI
Targeted therapies in mutant BRAF melanoma$321,625
R01 · FY2018 · CA · contact PI
Cancer Cell Biology and Signaling$50,997
P30 · FY2018 · CA · contact PI
Cancer Cell Biology and Signaling$11,841
P30 · FY2018 · CA · contact PI
Mutant BRAF-regulated transcription factors in melanoma progression$356,850
R01 · FY2017 · CA · contact PI
Targeted therapies in mutant BRAF melanoma$321,625
R01 · FY2017 · CA · contact PI
Mutant BRAF-regulated transcription factors in melanoma progression$356,850
R01 · FY2016 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$321,625
R01 · FY2016 · CA · contact PI
Targeted therapies in mutant BRAF melanoma$321,625
R01 · FY2016 · CA · contact PI
Mutant BRAF-regulated transcription factors in melanoma progression$356,660
R01 · FY2015 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$321,625
R01 · FY2015 · CA · contact PI
Targeted therapies in mutant BRAF melanoma$321,625
R01 · FY2015 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$14,229
R01 · FY2015 · CA · contact PI
Targeted therapies in mutant BRAF melanoma$321,625
R01 · FY2014 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$311,976
R01 · FY2014 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$51,541
R01 · FY2014 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$302,328
R01 · FY2013 · CA · contact PI
ADHESION AND ERK SIGNALING IN MELANOMA$284,589
R01 · FY2013 · GM · contact PI
B-RAF Regulation of the Cell Cycle in Melanoma$58,707
R01 · FY2013 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$38,906
R01 · FY2013 · CA · contact PI
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to RAF inhibitors$321,625
R01 · FY2012 · CA · contact PI
ADHESION AND ERK SIGNALING IN MELANOMA$294,911
R01 · FY2012 · GM · contact PI
B-RAF Regulation of the Cell Cycle in Melanoma$248,776
R01 · FY2012 · CA · contact PI
ADHESION AND ERK SIGNALING IN MELANOMA$294,911
R01 · FY2011 · GM · contact PI
B-RAF Regulation of the Cell Cycle in Melanoma$248,776
R01 · FY2011 · CA · contact PI
ADHESION AND ERK SIGNALING IN MELANOMA$297,794
R01 · FY2010 · GM · contact PI
B-RAF Regulation of the Cell Cycle in Melanoma$256,470
R01 · FY2010 · CA · contact PI
B-RAF Regulation of the Cell Cycle in Melanoma$256,470
R01 · FY2009 · CA · contact PI
Adhesion Regulation of ERK Trafficking to the Nucleus$128,189
R01 · FY2009 · GM · contact PI
B-RAF Regulation of the Cell Cycle in Melanoma$288,529
R01 · FY2008 · CA · contact PI
Adhesion Regulation of ERK Trafficking to the Nucleus$195,569
R01 · FY2008 · GM · contact PI
Adhesion Regulation of ERK Trafficking to the Nucleus$62,173
R01 · FY2008 · GM · contact PI
Adhesion Regulation of ERK Trafficking to the Nucleus$262,173
R01 · FY2007 · GM · contact PI
Adhesion Regulation of ERK Trafficking to the Nucleus$270,003
R01 · FY2006 · GM · contact PI
Adhesion Regulation of ERK Trafficking to the Nucleus$276,500
R01 · FY2005 · GM
Adhesion Regulation of ERK Trafficking to the Nucleus$286,982
R01 · FY2004 · GM